Overview

Luye Pharma USA develops and commercializes medicines in CNS, oncology, and cardiovascular diseases in the U.S., using advanced drug-delivery technologies like long-acting injectables, liposomes, and transdermal systems. Its products include Rykindo (risperidone long-acting injectable) approved by the FDA in 2023 and ERZOFRI (paliperidone palmitate) launched in 2025. The company sells through direct and B-to-B channels across 80+ countries and expands its pipeline through strategic acquisitions. Its goal is to build a global portfolio of in-house developed CNS, oncology, and cardiovascular therapies by advancing R&D, securing regulatory approvals, and scaling commercial operations.